This case highlights the occurrence of infliximab-induced pulmonary sarcoidosis, a rare but significant complication that healthcare providers should remain vigilant for, especially in patients presenting with respiratory symptoms while receiving anti-TNF therapy, especially after ruling out TB, which is an important differential diagnosis given the increased risk of reactivation with anti-TNF therapy. Here, TNF is linked to pulmonary sarcoidosis.